Hikma Pharmaceuticals Plc Notification of major interests in shares (1313B)
February 27 2014 - 9:35AM
UK Regulatory
TIDMHIK
RNS Number : 1313B
Hikma Pharmaceuticals Plc
27 February 2014
Notification of major interests in shares
LONDON, 27 February 2014 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the Hikma Pharmaceuticals
underlying issuer of existing PLC
shares to which the voting
rights are attached
------------------------------- ----------------------
2 Reason for the notification
------------------------------------------ ----
An acquisition or disposal of voting Yes
rights
------------------------------------------ ----
An acquisition or disposal of financial No
instruments which may result in the
acquisition of shares already issues
to which voting rights are attached
------------------------------------------ ----
An event changing the breakdown of voting No
rights
------------------------------------------ ----
Other (please specify): Compliance with No
the Transparency Directive
------------------------------------------ ----
3 Full name of the person subject The Capital Group Companies,
to the notification obligation Inc
-------------- -------------------------------------------------- ----------------------------------------
4 Full name of shareholders Capital Research and Management
Company New World Fund, Inc
-------------- -------------------------------------------------- ----------------------------------------
5 Date of the Transaction (and 25 February 2014
date on which the threshold
crossed is reached differently)
-------------- -------------------------------------------------- ----------------------------------------
6 Date on which the issuer notified 26 February 2014
-------------- -------------------------------------------------- ----------------------------------------
7 Threshold that is crossed 10%
-------------- -------------------------------------------------- ----------------------------------------
8 Notified details See A, B & C below
-------------- -------------------------------------------------- ----------------------------------------
A. Voting rights attached to shares
------------------------------------------------------------------------------------------------------------
Class type Situation previous Resulting situation after the
of shares to the triggering triggering transaction
(if possible transaction
using the
ISIN code)
---------------- ------------------------ ----------------------------------------------------------------
Number Number Number of Number of % of voting
of shares of voting shares voting rights rights
rights
-------------- ----------- ----------- -------------------- ---------------------- ------------------
Direct Indirect Direct Indirect Direct Indirect
-------------- ----------- ----------- ------- ----------- --------- ----------- ------- ---------
Ordinary
Shares
(0.10 GBP)
GB00B0LCW083 19,807,981 19,807,981 0 19,232,981 0 19,232,981 0% 9.719%
---------------- ----------- ----------- ------- ----------- --------- ----------- ------- ---------
B. Qualifying Financial instruments
---------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------
Type of Expiration Exercise/Conversion Number of % of voting
financial Date Period/Date voting rights rights
instrument that may be
acquired if
the instrument
if exercised/converted
------------ ----------- -------------------- ------------------------ ------------
- - - - -
------------ ----------- -------------------- ------------------------ ------------
C: Financial Instruments with similar economic effect
to Qualifying Financial Instruments
---------------------------------------------------------------------------------------------
Resulting situation after the triggering transaction
---------------------------------------------------------------------------------------------
Type of Exercise Expiration Exercise/Conversion Number of % of voting
financial Price Date Period/Date voting rights rights
instrument instrument
refers to
------------ --------- ----------- -------------------- --------------- ----------------
Nominal Delta
------------ --------- ----------- -------------------- --------------- -------- ------
- - - - - - -
------------ --------- ----------- -------------------- --------------- -------- ------
Total A+B+C
---------------------------------------------
Number of Voting rights % of voting rights
------------------------ -------------------
19,232,981 9.719
------------------------ -------------------
9 Chain of controlled undertakings through which
the voting rights and/or the financial instruments
are effectively held, if applicable
----------------------------------------------------
Proxy Voting
-------------------------------------------------------------
10 Name of the proxy holder The Capital Group Companies,
Inc
--- ------------------------- -----------------------------
11 Number of voting rights N/A
proxy holder will cease
to hold
--- ------------------------- -----------------------------
12 Date on which proxy N/A
holder will cease to
hold voting rights
--- ------------------------- -----------------------------
13 Additional Information
--- -------------------------- --------------------------------
14 Contact name: Peter Speirs, Company Secretary
--- -------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
--- -------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2012, Hikma achieved
revenues of $1,108.7 million and profit attributable to
shareholders of $100.3 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUBOSRSOAUUAR
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
